The estimated Net Worth of Bob D Brown is at least $4.33 Миллион dollars as of 15 December 2021. Bob Brown owns over 3,775 units of Dicerna Pharmaceuticals Inc stock worth over $154,485 and over the last 11 years he sold DRNA stock worth over $2,034,068. In addition, he makes $2,137,160 as Executive Vice President, Research and Development и Chief Scientific Officer at Dicerna Pharmaceuticals Inc.
Bob has made over 32 trades of the Dicerna Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 3,775 units of DRNA stock worth $144,281 on 15 December 2021.
The largest trade he's ever made was selling 34,747 units of Dicerna Pharmaceuticals Inc stock on 30 December 2019 worth over $760,959. On average, Bob trades about 9,181 units every 32 days since 2014. As of 15 December 2021 he still owns at least 4,042 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of Bob Brown stock trades at the bottom of the page.
Dr. Bob D. Brown Ph.D. serves as Executive Vice President, Research and Development, Chief Scientific Officer of the Company. Dr. Brown held various positions at Genta Incorporated, most recently as its Vice President of Research and Technology. Previously, he was a co-founder and Vice President of Research and Development of Oasis Biosciences Inc., which was acquired by Gen-Probe Incorporated. Dr. Brown is an inventor or co-inventor on 16 issued patents and dozens of patent applications covering oligonucleotide and conventional small molecule therapeutic agents, diagnostic tool and oligonucleotide and small molecule drug delivery technologies. Dr. Brown holds a Ph.D. in molecular biology from the University of California, Berkeley and a B.S. in chemistry and biology from the University of Washington, Seattle.
As the Executive Vice President, Research and Development и Chief Scientific Officer of Dicerna Pharmaceuticals Inc, the total compensation of Bob Brown at Dicerna Pharmaceuticals Inc is $2,137,160. There are 2 executives at Dicerna Pharmaceuticals Inc getting paid more, with Douglas Fambrough having the highest compensation of $5,048,130.
Bob Brown is 55, he's been the Executive Vice President, Research and Development и Chief Scientific Officer of Dicerna Pharmaceuticals Inc since 2019. There are 7 older and 5 younger executives at Dicerna Pharmaceuticals Inc. The oldest executive at Dicerna Pharmaceuticals Inc is Patrick Gray, 71, who is the Independent Director.
Bob's mailing address filed with the SEC is C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over $233,644,011 worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth $36,501,331 . The most active insiders traders include Capital Management, Llc Kol..., Nicole Vitullo и Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,025,674. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth $78,351.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include: